These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36934366)

  • 41. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials.
    Mignot E; Mayleben D; Fietze I; Leger D; Zammit G; Bassetti CLA; Pain S; Kinter DS; Roth T;
    Lancet Neurol; 2022 Feb; 21(2):125-139. PubMed ID: 35065036
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Progressive Loss of the Orexin Neurons Reveals Dual Effects on Wakefulness.
    Branch AF; Navidi W; Tabuchi S; Terao A; Yamanaka A; Scammell TE; Diniz Behn C
    Sleep; 2016 Feb; 39(2):369-77. PubMed ID: 26446125
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/- mice.
    Guo RX; Anaclet C; Roberts JC; Parmentier R; Zhang M; Guidon G; Buda C; Sastre JP; Feng JQ; Franco P; Brown SH; Upton N; Medhurst AD; Lin JS
    Br J Pharmacol; 2009 May; 157(1):104-17. PubMed ID: 19413575
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Maintenance of Wakefulness Test, real and simulated driving in patients with narcolepsy/hypersomnia.
    Sagaspe P; Micoulaud-Franchi JA; Coste O; Léger D; Espié S; Davenne D; Lopez R; Dauvilliers Y; Philip P
    Sleep Med; 2019 Mar; 55():1-5. PubMed ID: 30735912
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early-stage comparative effectiveness: randomized controlled trial with histamine inverse agonist MK-7288 in excessive daytime sleepiness patients.
    Sun H; MacLeod C; Mostoller K; Mahon C; Han L; Renger JJ; Ma J; Brown KR; Schulz V; Kay GG; Herring WJ; Lines C; Rosen LB; Murphy MG; Wagner JA
    J Clin Pharmacol; 2013 Dec; 53(12):1294-302. PubMed ID: 24122944
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.
    McClellan KJ; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):311-24. PubMed ID: 27521015
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial.
    Högl B; Saletu M; Brandauer E; Glatzl S; Frauscher B; Seppi K; Ulmer H; Wenning G; Poewe W
    Sleep; 2002 Dec; 25(8):905-9. PubMed ID: 12489899
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Orexin gene therapy restores the timing and maintenance of wakefulness in narcoleptic mice.
    Kantor S; Mochizuki T; Lops SN; Ko B; Clain E; Clark E; Yamamoto M; Scammell TE
    Sleep; 2013 Aug; 36(8):1129-38. PubMed ID: 23904672
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy.
    Emsellem HA; Thorpy MJ; Lammers GJ; Shapiro CM; Mayer G; Plazzi G; Chen D; Carter LP; Villa KF; Lee L; Menno D; Black J; Dauvilliers Y
    Sleep Med; 2020 Mar; 67():128-136. PubMed ID: 31926465
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation.
    Nirogi R; Benade V; Daripelli S; Subramanian R; Kamuju V; Bhyrapuneni G; Muddana NR; Mekala VR; Petlu S; Jayarajan P; Badange R; Shinde A; Jasti V
    Psychopharmacology (Berl); 2021 Jun; 238(6):1495-1511. PubMed ID: 33550481
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Orexin neurons suppress narcolepsy via 2 distinct efferent pathways.
    Hasegawa E; Yanagisawa M; Sakurai T; Mieda M
    J Clin Invest; 2014 Feb; 124(2):604-16. PubMed ID: 24382351
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy.
    Baier PC; Hallschmid M; Seeck-Hirschner M; Weinhold SL; Burkert S; Diessner N; Göder R; Aldenhoff JB; Hinze-Selch D
    Sleep Med; 2011 Dec; 12(10):941-6. PubMed ID: 22036605
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Toward the Mysteries of Sleep.
    Yanagisawa M
    Keio J Med; 2019; 68(1):27. PubMed ID: 30905886
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimal dose determination of enerisant (TS-091) for patients with narcolepsy: two randomized, double-blind, placebo-controlled trials.
    Inoue Y; Uchiyama M; Umeuchi H; Onishi K; Ogo H; Kitajima I; Matsushita I; Nishino I; Uchimura N
    BMC Psychiatry; 2022 Feb; 22(1):141. PubMed ID: 35193545
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials.
    Meskill GJ; Davis CW; Zarycranski D; Doliba M; Schwartz JC; Dayno JM
    CNS Drugs; 2022 Jan; 36(1):61-69. PubMed ID: 34935103
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy.
    Black J; Pardi D; Hornfeldt CS; Inhaber N
    Sleep Med; 2009 Sep; 10(8):829-35. PubMed ID: 19616998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates.
    Willie JT; Renthal W; Chemelli RM; Miller MS; Scammell TE; Yanagisawa M; Sinton CM
    Neuroscience; 2005; 130(4):983-95. PubMed ID: 15652995
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of Excessive Daytime Sleepiness in Narcolepsy With Baclofen.
    Morse AM; Kelly-Pieper K; Kothare SV
    Pediatr Neurol; 2019 Apr; 93():39-42. PubMed ID: 30595352
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy.
    Kushida CA; Shapiro CM; Roth T; Thorpy MJ; Corser BC; Ajayi AO; Rosenberg R; Roy A; Seiden D; Dubow J; Dauvilliers Y
    Sleep; 2022 Jun; 45(6):. PubMed ID: 34358324
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys.
    Tannenbaum PL; Tye SJ; Stevens J; Gotter AL; Fox SV; Savitz AT; Coleman PJ; Uslaner JM; Kuduk SD; Hargreaves R; Winrow CJ; Renger JJ
    Sleep; 2016 Mar; 39(3):603-12. PubMed ID: 26943466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.